SAB Biotherapeutics Announces Director Change and Filings

TL;DR

SAB Biotherapeutics board shakeup, new director appointed, financial docs filed.

AI Summary

On March 5, 2024, SAB Biotherapeutics, Inc. announced the departure of Director Dr. Jonathan M. Rothberg and the appointment of Dr. Steven M. Deitcher as a new director. The company also reported on compensatory arrangements for certain officers and filed financial statements and exhibits.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, while financial filings provide crucial updates on the company's performance and outlook.

Risk Assessment

Risk Level: medium — Director changes and financial filings can introduce uncertainty or reveal important financial information that impacts stock price.

Key Players & Entities

• SAB Biotherapeutics, Inc. (company) — Registrant
• Dr. Jonathan M. Rothberg (person) — Departing Director
• Dr. Steven M. Deitcher (person) — Appointed Director
• March 05, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
• $485,000 — . Sullivan (i) an annual base salary of $485,000; (ii) eligibility to participate in the
• $425,000 — Mr. Bausch (i) an annual base salary of $425,000; (ii) eligibility to participate in the

Filing Documents

• sabs-20240305.htm (8-K) — 46KB
• sabs-ex10_1.htm (EX-10.1) — 179KB
• sabs-ex10_2.htm (EX-10.2) — 175KB
• 0000950170-24-028666.txt ( ) — 603KB
• sabs-20240305.xsd (EX-101.SCH) — 44KB
• sabs-20240305_htm.xml (XML) — 6KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. The disclosure set forth under Item 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. President Executive Employment Agreement On March 5, 2024, SAB Biotherapeutics, Inc. (the "Company") and Eddie J. Sullivan, PhD, the President and a member of the Board of Directors of the Company, entered into an executive employment agreement, effective as of January 1, 2024 (the "Sullivan Agreement"). The Sullivan Agreement provides Mr. Sullivan (i) an annual base salary of $485,000; (ii) eligibility to participate in the Company's annual discretionary bonus plan for executives, with the potential to earn a cash bonus equal to up to fifty (50%) percent of Mr. Sullivan's annual base salary; (iii) eligibility to participate in the Company's benefit plans; and (iv) reimbursement for reasonable out-of-pocket expenses. The Sullivan Agreement subjects Mr. Sullivan to standard restrictive covenants for agreements of its type, including non-competition and non-solicitation. There are no family relationships between Mr. Sullivan and the directors, nor between Mr. Sullivan and any executive officer, of the Company. The Sullivan Agreement replaces the prior existing employment agreement between the Company and Mr. Sullivan dated March 1, 2021 (the "Prior Sullivan Agreement") as described in the Company's filings with the Securities and Exchange Commission in its entirety; provided that all obligations of Mr. Sullivan under the Prior Sullivan Agreement that survive the Prior Sullivan Agreement's term continue upon execution of the Sullivan Agreement. The foregoing description of the Sullivan Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sullivan Agreement, a copy of

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 10.1 Executive Employment Agreement between SAB Biotherapeutics, Inc. and Eddie J. Sullivan, dated March 5, 2024. 10.2 Executive Employment Agreement between SAB Biotherapeutics, Inc. and Christoph Bausch, dated March 5, 2024. 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: March 8, 2024 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR